RenovoRx, Inc.

RenovoRx, Inc. is a clinical-stage biopharmaceutical company dedicated to developing proprietary targeted combination therapies for high unmet medical needs, primarily in oncology. The company's mission is to transform the lives of cancer patients by providing innovative solutions that enable the targeted delivery of diagnostic and therapeutic agents. RenovoRx is headquartered in Mountain View, California.

At the core of RenovoRx's technology is its patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is enabled by the FDA-cleared RenovoCath® dual-balloon catheter system. This platform is designed to deliver chemotherapy directly to tumor sites, aiming to increase efficacy while minimizing systemic toxicities compared to traditional intravenous therapies. The company's lead product candidate, RenovoGem™ (intra-arterial gemcitabine, or IAG), is a drug-device combination currently undergoing a Phase III clinical trial (TIGeR-PaC) for the treatment of locally advanced pancreatic cancer. RenovoRx also commercializes RenovoCath as a stand-alone device.

Recent developments for RenovoRx include the FDA granting Orphan Drug Designation for oxaliplatin for the treatment of pancreatic cancer in May 2026, adding to its existing Orphan Drug Designation for RenovoCath with gemcitabine for pancreatic and bile duct cancers. The company reported record first-quarter 2026 revenue for RenovoCath sales, marking a 136% increase quarter-over-quarter. RenovoRx anticipates completing enrollment in its pivotal TIGeR-PaC trial by June 2026, with final data expected in mid to late 2027. Shaun Bagai serves as the Chief Executive Officer.